Literature DB >> 14695164

Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.

M Livia Bajenaru1, M Rosario Hernandez, Arie Perry, Yuan Zhu, Luis F Parada, Joel R Garbow, David H Gutmann.   

Abstract

Whereas biallelic neurofibromatosis 1 (NF1) inactivation is observed in NF1-associated gliomas, astrocyte-restricted Nf1 conditional knockout mice do not develop gliomas. These observations suggest that NF1 glioma formation requires additional cellular or genetic conditions. To determine the effect of an Nf1 heterozygous brain environment on NF1 glioma formation, we generated Nf1+/- mice lacking Nf1 expression in astrocytes. In contrast to astrocyte-restricted Nf1 conditional knockout mice, Nf1+/- mice lacking Nf1 in astrocytes develop optic nerve gliomas. This mouse model demonstrates that Nf1+/- cells contribute to the pathogenesis of gliomas in NF1 and provides a tool for the preclinical evaluation of potential therapeutic interventions for these tumors.

Entities:  

Mesh:

Year:  2003        PMID: 14695164

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  125 in total

1.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

Review 2.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

3.  CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.

Authors:  Tao Sun; Scott M Gianino; Erin Jackson; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
Journal:  J Neuroimmunol       Date:  2010-07-27       Impact factor: 3.478

4.  Evidence for and against regional differences in neural stem and progenitor cells of the CNS.

Authors:  Oren J Becher; Eric C Holland
Journal:  Genes Dev       Date:  2010-10-15       Impact factor: 11.361

Review 5.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

Review 6.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

Review 7.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

8.  Activation of retinal neurons triggers tumour formation in cancer-prone mice.

Authors:  Varun Venkataramani; Frank Winkler
Journal:  Nature       Date:  2021-06       Impact factor: 49.962

Review 9.  Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma.

Authors:  David H Gutmann
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

Review 10.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.